Who we are
Angelini Pharma is the pharmaceutical division of Angelini Industries. The Group started almost 100 years ago as a small pharmaceutical laboratory, and over the years has grown into a leading international group in healthcare, present in Pharmaceuticals and Mass-Market.
Angelini Pharma is a leader in healthcare, with particular strength and expertise in the fields of Mental Health and Epilepsy. The company is also a leading player in the Consumer Health segment, with highly successful OTC brands worldwide.
Angelini Pharma products are marketed in about 70 countries. The company operates directly in 20 countries employing almost 3.000 people, and commercializes its products in more than 70 countries through strategic alliances with leading international pharmaceutical groups.
Angelini Pharma operates in Switzerland with its branch Angelini Pharma Zug S.p.A. (formerly Arvelle Therapeutics International GmbH), which employs approximately 15 people at its headquarters located in Zug, Switzerland. Angelini Pharma acquired Arvelle Therapeutics International GmbH, a biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders in 2021.
In Switzerland, Angelini Pharma markets medicinal products and healthcare solutions with a focus on brain health, notably in epilepsy.
Through multiple partnerships and collaborations with both the private and public sectors the company is determined to improve the lives of patients with epilepsy and to develop new innovations and insights in this area.
To date, Angelini Pharma Switzerland is the Marketing Authorisation Holder of the medicinal product Ontozry® (cenobamate). For further information, please refer to the full Information for Professionals or to the Patient Information Leaflet at www.swissmedicinfo.ch.
To find out more about Angelini Pharma please visit our global site.
